Quick Answer
Caris Life Sciences, Inc. reported Revenue (ASC 606) of $812.03 million for fiscal year 2025.
Caris Life Sciences, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $812.03M | +97.0% |
| 2024 | $412.26M | +34.7% |
| 2023 | $306.13M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $216.83M | +113.4% | +19.5% |
| June 30, 2025 | $181.40M | +81.3% | +78.5% |
| September 30, 2024 | $101.62M | — | +1.6% |
| June 30, 2024 | $100.05M | — | — |
- Caris Life Sciences, Inc. showed an increase of +97.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Caris Life Sciences, Inc.’s revenue (asc 606) has grown by 165.3% (from $306.13 million to $812.03 million).
- The most recent figure is from Caris Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: